Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal Jurnal Buana Farma
Endah Kartikawati
Program Studi Farmasi, Fakultas Matematika dan Ilmu Pengetahuan Alam, Universitas Al-Ghifari, Bandung, Indonesia
Biochemistry, Genetics & Molecular Biology Chemistry Immunology & microbiology Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
AKTIVITAS ANTIBAKTERI EKSTRAK ETANOL DAUN KRATOM (Mitragyna speciosa Korth.) TERHADAP BEBERAPA BAKTERI PENYEBAB JERAWAT Maria Ulfah; Irma Erika Herawati; Endah Kartikawati
Jurnal Buana Farma Vol. 4 No. 2 (2024): Jurnal Buana Farma : Jurnal Ilmiah Farmasi
Publisher : Fakultas Farmasi Universitas Buana Perjuangan Karawang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36805/jbf.v4i2.1027

Abstract

Acne is a common disease on the surface of the skin of the face. It will appear when the oil glands are too active and is generally followed by a bacterial infection that will cause inflammation. Bacteria that can cause acne include Propionibacterium acnes, Staphylococcus aureus, and Staphylococcus epidermidis. The plant that has antibacterial activity is kratom (Mitragyna speciosa Korth). Kratom leaves have secondary metabolites that can act as antibacteria, such as alkaloids, flavonoids, and saponins. The study aims to determine the antibacterial activity of ethanol extract against some bacteria causing acne using disc diffusion methods. The concentrations of the test sample ethanol extract of kratom leaves used were 60%, 30%, 15%, and 12.5%, with the positive controls used being chloramphenicol. The results of the study showed that ethanol extract at all concentrations had a barrier zone against the growth of the bacteria P. acnes, S. aureus, and S. epidermidis with a moderate barrier response category. Where best activity is shown at a concentration of 60% kratom leaf ethanol extract against P.acnes and S.aureus
ANALISIS IN SILICO SENYAWA BIOAKTIF BUAH JAMBU BIJI (Psidium guajava L.) SEBAGAI INHIBITOR α-GLUKOSIDASE UNTUK TERAPI DIABETES MELLITUS TIPE 2 Syulastri Effendi; Hesty Nuur Hanifah; Lisna Dewi; Endah Kartikawati; Ita Inayah; Ayu Lestari
Jurnal Buana Farma Vol 6 No 2 (2026): Jurnal Buana Farma
Publisher : Fakultas Farmasi Universitas Buana Perjuangan Karawang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36805/jbf.v6i2.1710

Abstract

Type 2 diabetes mellitus is a global metabolic disorder that requires safer and more effective therapeutic alternatives. Inhibition of α-glucosidase activity is an effective method for treating type 2 diabetes mellitus because it can delay carbohydrate hydrolysis and inhibit postprandial hyperglycemia. Guava fruit (Psidium guajava L.) contains various bioactive compounds with great potential to be developed as an alternative therapy for diabetes mellitus. This study aims to analyze the potential of active compounds in guava fruit as α-glucosidase inhibitors through molecular docking and ADME evaluation. A total of 27 bioactive compounds reported in guava fruit were tested against human α-glucosidase obtained from the Protein Data Bank (PDB ID: 2QMJ). Toxicity analysis was performed using ProTox-II, ADME prediction using pkCSM, and molecular docking using AutoDock Tools. Toxicity analysis revealed that 85% of the tested compounds had an acceptable safety profile, with LD₅₀ values greater than 500 mg/kg. ADME evaluation showed that most tested compounds had good intestinal absorption above 80%. Method validation through acarbose redocking yielded an RMSD value of 1.506 Å. Ligand docking results indicated that citral has potential as an antidiabetic drug candidate, with Gibbs free energy of -4.59 kcal/mol and an inhibition constant (Ki) of 431.62 μM. The interaction of citral with key residues TRP A441, PHE A450, and ASP A542 indicates possible binding to the α-glucosidase active site. This study demonstrates the potential of guava active compounds as α-glucosidase inhibitor candidates for developing type 2 diabetes mellitus therapy and supports further preclinical studies for future clinical application.
Co-Authors Ayu Lestari Hesty Nuur Hanifah Irma Erika Herawati Ita Inayah Lisna Dewi Maria Ulfah Syulastri Effendi